TRVI – trevi therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Trevi Therapeutics Announces Pricing of $50 Million Underwritten Offering
Trevi's chronic cough trial in IPF subjects continues without sample size change [Yahoo! Finance]
Trevi Therapeutics, Inc. (NASDAQ: TRVI) had its price target raised by analysts at HC Wainwright from $6.00 to $7.50. They now have a "buy" rating on the stock.
Trevi Therapeutics, Inc. (NASDAQ: TRVI) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $8.00 price target on the stock.
Trevi Therapeutics, Inc. (NASDAQ: TRVI) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $21.00 price target on the stock.
Form 4 Trevi Therapeutics, Inc. For: Dec 13 Filed by: Galletta Christopher
Form 8-K Trevi Therapeutics, Inc. For: Dec 15
Form 424B5 Trevi Therapeutics, Inc.
Form 8-K Trevi Therapeutics, Inc. For: Dec 12
Form 8-K Trevi Therapeutics, Inc. For: Dec 03
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.